Exploring Dysregulated Signaling Pathways in Cancer

Sabah       Nisar; Sheema       Hashem; Muzafar    A.    Macha; Santosh    K.    Yadav; Sankavi       Muralitharan; Lubna       Therachiyil; Geetanjali       Sageena; Hamda       Al-Naemi; Mohammad       Haris; Ajaz    A.    Bhat
Abstract

Cancer cell biology takes advantage of identifying diverse cellular signaling pathways that are disrupted in cancer. Signaling pathways are an important means of communication from the exterior of cell to intracellular mediators, as well as intracellular interactions that govern diverse cellular processes. Oncogenic mutations or abnormal expression of signaling components disrupt the regulatory networks that govern cell function, thus enabling tumor cells to undergo dysregulated mitogenesis, to resist apoptosis, and to promote invasion to neighboring tissues. Unraveling of dysregulated signaling pathways may advance the understanding of tumor pathophysiology and lead to the improvement of targeted tumor therapy. In this review article, different signaling pathways and how their dysregulation contributes to the development of tumors have been discussed.
Keywords: Angiogenesis, apoptosis, cell invasion, cell proliferation, drug targets, metastasis, signaling pathways, tumor microenvironment.
[1] 
Garraway LA, Lander ES. Lessons from the cancer genome. Cell  2013; 153(1): 17-37.
[http://dx.doi.org/10.1016/j.cell.2013.03.002] [PMID: 23540688] 
[2] 
Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in the cancer genome atlas  Cell 2018; 173(2): 321-337.
e10.
[http://dx.doi.org/10.1016/j.cell.2018.03.035] [PMID: 29625050] 
[3] 
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell  2011; 144(5): 646-74.
[http://dx.doi.org/10.1016/j.cell.2011.02.013] [PMID: 21376230] 
[4] 
Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell  2010; 18(6): 884-901.
[http://dx.doi.org/10.1016/j.devcel.2010.05.012] [PMID: 20627072] 
[5] 
Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev  2011; 241(1): 104-18.
[http://dx.doi.org/10.1111/j.1600-065X.2011.01007.x] [PMID: 21488893] 
[6] 
Giancotti FG. Deregulation of cell signaling in cancer. FEBS Lett  2014; 588(16): 2558-70.
[http://dx.doi.org/10.1016/j.febslet.2014.02.005] [PMID: 24561200] 
[7] 
Sever R, Brugge JS. Signal transduction in cancer. Cold Spring Harb Perspect Med  2015; 5(4)a006098
[http://dx.doi.org/10.1101/cshperspect.a006098] [PMID: 25833940] 
[8] 
Martin GS. Cell signaling and cancer. Cancer Cell  2003; 4(3): 167-74.
[http://dx.doi.org/10.1016/S1535-6108(03)00216-2] [PMID: 14522250] 
[9] 
Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer  2009; 9(7): 463-75.
[http://dx.doi.org/10.1038/nrc2656] [PMID: 19536107] 
[10] 
Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol  2018; 12(1): 3-20.
[http://dx.doi.org/10.1002/1878-0261.12155] [PMID: 29124875] 
[11] 
Alowaidi F, Hashimi SM, Alqurashi N, Wood SA, Wei MQ. Cripto-1 overexpression in U87 glioblastoma cells activates MAPK, focal adhesion and ErbB pathways. Oncol Lett  2019; 18(3): 3399-406.
[http://dx.doi.org/10.3892/ol.2019.10626] [PMID: 31452820	] 
[12] 
Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene  2005; 24(50): 7391-3.
[http://dx.doi.org/10.1038/sj.onc.1209100] [PMID: 16288285] 
[13] 
Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev  2001; 15(11): 1406-18.
[http://dx.doi.org/10.1101/gad.889901] [PMID: 11390360] 
[14] 
Chen H-T, Liu H, Mao M-J, et al. Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy. Mol Cancer  2019; 18(1): 101-.
[http://dx.doi.org/10.1186/s12943-019-1030-2] [PMID: 31126310] 
[15] 
Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res  2002; 90(12): 1243-50.
[http://dx.doi.org/10.1161/01.RES.0000022200.71892.9F] [PMID: 12089061] 
[16] 
Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol  2018; 15(5): 273-91.
[http://dx.doi.org/10.1038/nrclinonc.2018.28] [PMID: 29508857] 
[17] 
Owonikoko TK, Khuri FR.  Targeting the PI3K/AKT/mTOR pathway:
biomarkers of success and tribulation. American Society of Clinical Oncology educational book. Am Soc Clin Oncol 2013
[http://dx.doi.org/10.1200/EdBook_AM.2013.33. e395] 
[18] 
Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science  2004; 304(5670): 554.
[http://dx.doi.org/10.1126/science.1096502] [PMID: 15016963] 
[19] 
Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature  2013; 502(7471): 333-9.
[http://dx.doi.org/10.1038/nature12634] [PMID: 24132290] 
[20] 
Vasko V, Saji M, Hardy E, et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet  2004; 41(3): 161-70.
[http://dx.doi.org/10.1136/jmg.2003.015339] [PMID: 14985374] 
[21] 
Ringel MD, Hayre N, Saito J, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res  2001; 61(16): 6105-11.
[PMID: 11507060] 
[22] 
Miyakawa M, Tsushima T, Murakami H, Wakai K, Isozaki O, Takano K. Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocr J  2003; 50(1): 77-83.
[http://dx.doi.org/10.1507/endocrj.50.77] [PMID: 12733712] 
[23] 
Blackhall FH, Pintilie M, Michael M, et al. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res  2003; 9(6): 2241-7.
[PMID: 12796392] 
[24] 
Balsara B, Pei J, Mitsuuchi Y, et al. Testa JRFrequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis  2004; 25(11): 2053-9.
[http://dx.doi.org/10.1093/carcin/bgh226] [PMID: 15240509] 
[25] 
Lee SH, Kim HS, Park WS, et al. Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS  2002; 110(7-8): 587-92.
[http://dx.doi.org/10.1034/j.1600-0463.2002.11007811.x] [PMID: 12390418] 
[26] 
Tsao AS, McDonnell T, Lam S, et al. Increased Phospho-AKT (Ser&lt;sup&gt;473&lt;/sup&gt;) expression in bronchial dysplasia. Cancer Epidemiology Biomarkers & amp;amp. Prevention  2003; 12: 660.
[PMID: 12869408] 
[27] 
Mukohara T1, Kudoh S, Matsuura K, et al.. Activated Akt Expression has Significant Correlation with EGFR and TGF-α Expressions in Stage I NSCLC. Anticancer Res  2004; 24: 11-8.
[28] 
Stål O, Pérez-Tenorio G, Akerberg L, et al. Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res  2003; 5(2): R37-44.
[http://dx.doi.org/10.1186/bcr569] [PMID: 12631397] 
[29] 
Pérez-Tenorio G, Stål O. Southeast sweden breast cancer G. activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer  2002; 86(4): 540-5.
[http://dx.doi.org/10.1038/sj.bjc.6600126] [PMID: 11870534] 
[30] 
Shi W, Zhang X, Pintilie M, et al. Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int J Cancer  2003; 104(2): 195-203.
[http://dx.doi.org/10.1002/ijc.10909] [PMID: 12569575] 
[31] 
Sun M, Wang G, Paciga JE, et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol  2001; 159(2): 431-7.
[http://dx.doi.org/10.1016/S0002-9440(10)61714-2] [PMID: 11485901] 
[32] 
Nam SY, Lee HS, Jung G-A, et al. Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis. APMIS  2003; 111(12): 1105-13.
[http://dx.doi.org/10.1111/j.1600-0463.2003.apm1111205.x] [PMID: 14678019] 
[33] 
Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer  2003; 89(11): 2110-5.
[http://dx.doi.org/10.1038/sj.bjc.6601396] [PMID: 14647146] 
[34] 
Semba S, Moriya T, Kimura W, Yamakawa M. Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas. Pancreas  2003; 26(3): 250-7.
[http://dx.doi.org/10.1097/00006676-200304000-00008] [PMID: 12657951] 
[35] 
Altomare DA, Wang HQ, Skele KL, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene  2004; 23(34): 5853-7.
[http://dx.doi.org/10.1038/sj.onc.1207721] [PMID: 15208673] 
[36] 
Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res  2002; 8(4): 1168-71.
[PMID: 11948129] 
[37] 
Horiguchi A, Oya M, Uchida A, Marumo K, Murai M. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J Urol  2003; 169(2): 710-3.
[http://dx.doi.org/10.1016/S0022-5347(05)63998-5] [PMID: 12544348] 
[38] 
Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer  2003; 10(2): 203-8.
[http://dx.doi.org/10.1677/erc.0.0100203] [PMID: 12790783] 
[39] 
Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol  2004; 22(10): 1926-33.
[http://dx.doi.org/10.1200/JCO.2004.07.193] [PMID: 15143086] 
[40] 
Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene  2005; 24(50): 7455-64.
[http://dx.doi.org/10.1038/sj.onc.1209085] [PMID: 16288292] 
[41] 
Qiang Yuan Z, Sun MI.  Feldman R, Wang G, et al.  Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene  19: 2324-30.
[42] 
Altomare DA, Tanno S, De Rienzo A, et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem  2002; 87: 470-6.
[43] 
Nakatani K, Thompson DA, Barthel A, et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem  1999; 274(31): 21528-32.
[http://dx.doi.org/10.1074/jbc.274.31.21528] [PMID: 10419456] 
[44] 
Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature  2007; 448(7152): 439-44.
[http://dx.doi.org/10.1038/nature05933] [PMID: 17611497] 
[45] 
Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA  1987; 84(14): 5034-7.
[http://dx.doi.org/10.1073/pnas.84.14.5034] [PMID: 3037531] 
[46] 
Shayesteh L, Lu Y, Kuo W-L, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet  1999; 21(1): 99-102.
[http://dx.doi.org/10.1038/5042] [PMID: 9916799] 
[47] 
Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer  2002; 2(7): 489-501.
[http://dx.doi.org/10.1038/nrc839] [PMID: 12094235] 
[48] 
Stefanetti RJ, Voisin S, Russell A, Lamon S. Recent advances in understanding the role of FOXO3. F1000 Res  2018; 7: F1000.
[49] 
Moreira BP, Oliveira PF, Alves MG. Molecular mechanisms controlled by mTOR in male reproductive system. Int J Mol Sci  2019; 20(7): 1633.
[http://dx.doi.org/10.3390/ijms20071633] [PMID: 30986927] 
[50] 
Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov  2014; 13(2): 140-56.
[http://dx.doi.org/10.1038/nrd4204] [PMID: 24481312] 
[51] 
Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol  2012; 13(5): 283-96.
[http://dx.doi.org/10.1038/nrm3330] [PMID: 22473468] 
[52] 
Grumolato L, Aaronson SA. Aberrant signaling pathways in cancer. Holland Frei Cancer Med 2017.
[53] 
Rapa I, Saggiorato E, Giachino D, et al. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. J Clin Endocrinol Metab  2011; 96(7): 2146-53.
[http://dx.doi.org/10.1210/jc.2010-2655] [PMID: 21543427] 
[54] 
Miao H, Wei B-R, Peehl DM, et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol  2001; 3(5): 527-30.
[http://dx.doi.org/10.1038/35074604] [PMID: 11331884] 
[55] 
McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta  2007; 1773(8): 1263-84.
[http://dx.doi.org/10.1016/j.bbamcr.2006.10.001] [PMID: 17126425] 
[56] 
Fernández-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer  2011; 2(3): 344-58.
[http://dx.doi.org/10.1177/1947601911411084] [PMID: 21779504] 
[57] 
Arrington AK, Heinrich EL, Lee W, et al. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci  2012; 13(10): 12153-68.
[http://dx.doi.org/10.3390/ijms131012153] [PMID: 23202889] 
[58] 
Thumar J, Shahbazian D, Aziz SA, Jilaveanu LB, Kluger HM. MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer  2014; 13: 45-5.
[http://dx.doi.org/10.1186/1476-4598-13-45] [PMID: 24588908] 
[59] 
Muñoz-Couselo E, Adelantado EZ, Ortiz C, García JS, Perez-Garcia J. NRAS-mutant melanoma: current challenges and future prospect. OncoTargets Ther  2017; 10: 3941-7.
[http://dx.doi.org/10.2147/OTT.S117121] [PMID: 28860801] 
[60] 
Grünewald I, Vollbrecht C, Meinrath J, et al. Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget  2015; 6(20): 18224-37.
[http://dx.doi.org/10.18632/oncotarget.4015] [PMID: 26053092] 
[61] 
Yoo J, Robinson RA. ras gene mutations in salivary gland tumors. Arch Pathol Lab Med  2000; 124(6): 836-9.
[PMID: 10835516] 
[62] 
Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancer-roles and therapeutic opportunities. Oncogene  2011; 30(32): 3477-88.
[http://dx.doi.org/10.1038/onc.2011.160] [PMID: 21577205] 
[63] 
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature  2002; 417(6892): 949-54.
[http://dx.doi.org/10.1038/nature00766] [PMID: 12068308] 
[64] 
Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab  2003; 88(9): 4393-7.
[http://dx.doi.org/10.1210/jc.2003-030305] [PMID: 12970315] 
[65] 
Jones JC, Renfro LA, Al-Shamsi HO, et al. Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J Clin Oncol  2017; 35(23): 2624-30.
[http://dx.doi.org/10.1200/JCO.2016.71.4394] [PMID: 28486044] 
[66] 
Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clinical cancer research. Official J American Assoc Cancer Res  2013; 19: 4532-40.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-0657] 
[67] 
Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell  2011; 19(1): 11-5.
[http://dx.doi.org/10.1016/j.ccr.2011.01.008] [PMID: 21251612] 
[68] 
Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev  2007; 28(7): 742-62.
[http://dx.doi.org/10.1210/er.2007-0007] [PMID: 17940185] 
[69] 
Garnett MJ, Rana S, Paterson H, Barford D, Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell  2005; 20(6): 963-9.
[http://dx.doi.org/10.1016/j.molcel.2005.10.022] [PMID: 16364920] 
[70] 
Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab  2008; 93(1): 278-84.
[http://dx.doi.org/10.1210/jc.2007-1076] [PMID: 17989125] 
[71] 
Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer  2009; 16(1): 17-44.
[http://dx.doi.org/10.1677/ERC-08-0154] [PMID: 18987168] 
[72] 
Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol  2005; 23(27): 6771-90.
[http://dx.doi.org/10.1200/JCO.2005.08.036] [PMID: 16170185] 
[73] 
Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets  2012; 16(1): 103-19.
[http://dx.doi.org/10.1517/14728222.2011.645805] [PMID: 22239440] 
[74] 
Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell  2009; 16(5): 633-47.
[http://dx.doi.org/10.1016/j.devcel.2009.03.010] [PMID: 19460341] 
[75] 
Tien A-C, Rajan A, Bellen HJ. A Notch updated. J Cell Biol  2009; 184(5): 621-9.
[http://dx.doi.org/10.1083/jcb.200811141] [PMID: 19255248] 
[76] 
Guo H, Lu Y, Wang J, et al. Targeting the notch signaling pathway in cancer therapeutics. Thorac Cancer  2014; 5(6): 473-86.
[http://dx.doi.org/10.1111/1759-7714.12143] [PMID: 26767041] 
[77] 
Leong KG, Niessen K, Kulic I, et al. Jagged1-mediated notch activation induces epithelial-to-mesenchymal transition through slug-induced repression of E-cadherin. J Exp Med  2007; 204(12): 2935-48.
[http://dx.doi.org/10.1084/jem.20071082] [PMID: 17984306] 
[78] 
Sethi S, Macoska J, Chen W, Sarkar FH. Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res  2010; 3(1): 90-9.
[PMID: 21139809] 
[79] 
Blaumueller CM, Qi H, Zagouras P, Artavanis-Tsakonas S. Intracellular cleavage of notch leads to a heterodimeric receptor on the plasma membrane. Cell  1997; 90(2): 281-91.
[http://dx.doi.org/10.1016/S0092-8674(00)80336-0] [PMID: 9244302] 
[80] 
Logeat F, Bessia C, Brou C, et al. The notch1 receptor is cleaved constitutively by a furin-like convertase. Proc Natl Acad Sci USA  1998; 95(14): 8108-12.
[http://dx.doi.org/10.1073/pnas.95.14.8108] [PMID: 9653148] 
[81] 
Brou C, Logeat F, Gupta N, et al. A novel proteolytic cleavage involved in notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell  2000; 5(2): 207-16.
[http://dx.doi.org/10.1016/S1097-2765(00)80417-7] [PMID: 10882063] 
[82] 
De Strooper B, Annaert W, Cupers P, et al. A presenilin-1-dependent γ-secretase-like protease mediates release of notch intracellular domain. Nature  1999; 398(6727): 518-22.
[http://dx.doi.org/10.1038/19083] [PMID: 10206645] 
[83] 
Mumm JS, Schroeter EH, Saxena MT, et al. A ligand-induced extracellular cleavage regulates γ-secretase-like proteolytic activation of Notch1. Mol Cell  2000; 5(2): 197-206.
[http://dx.doi.org/10.1016/S1097-2765(00)80416-5] [PMID: 10882062] 
[84] 
Thompson BJ, Buonamici S, Sulis ML, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med  2007; 204(8): 1825-35.
[http://dx.doi.org/10.1084/jem.20070872] [PMID: 17646408] 
[85] 
Bolós V, Mira E, Martínez-Poveda B, et al. Notch activation stimulates migration of breast cancer cells and promotes tumor growth. Breast Cancer Res  2013; 15(4): R54-4.
[http://dx.doi.org/10.1186/bcr3447] [PMID: 23826634] 
[86] 
Farnie G, Clarke RB. Mammary stem cells and breast cancer-role of notch signalling. Stem Cell Rev  2007; 3(2): 169-75.
[http://dx.doi.org/10.1007/s12015-007-0023-5] [PMID: 17873349] 
[87] 
Speiser JJ, Erşahin Ç, Osipo C. Chapter eleven - the functional role of notch signaling in triple-negative breast cancer. Vitam Horm  2013; 93: 277-306.
[88] 
Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res  2006; 66(3): 1517-25.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-3054] [PMID: 16452208] 
[89] 
Gallahan D, Kozak C, Callahan R. A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17. J Virol  1987; 61(1): 218-20.
[PMID: 3023699] 
[90] 
Pece S, Serresi M, Santolini E, et al. Loss of negative regulation by numb over notch is relevant to human breast carcinogenesis. J Cell Biol  2004; 167(2): 215-21.
[http://dx.doi.org/10.1083/jcb.200406140] [PMID: 15492044] 
[91] 
Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev  2006; 20(15): 2096-109.
[http://dx.doi.org/10.1101/gad.1450406] [PMID: 16847353] 
[92] 
Beverly LJ, Felsher DW, Capobianco AJ. Suppression of p53 by notch in lymphomagenesis: implications for initiation and regression. Cancer Res  2005; 65(16): 7159-68.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-1664] [PMID: 16103066] 
[93] 
Efstratiadis A, Szabolcs M, Klinakis A. Notch, Myc and breast cancer. Cell Cycle  2007; 6(4): 418-29.
[http://dx.doi.org/10.4161/cc.6.4.3838] [PMID: 17329972] 
[94] 
Phillips TM, Kim K, Vlashi E, McBride WH, Pajonk F. Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia  2007; 9(12): 1122-9.
[http://dx.doi.org/10.1593/neo.07694] [PMID: 18084619] 
[95] 
Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther  2006; 5(3): 483-93.
[http://dx.doi.org/10.1158/1535-7163.MCT-05-0299] [PMID: 16546962] 
[96] 
Yabuuchi S, Pai SG, Campbell NR, et al. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett  2013; 335(1): 41-51.
[http://dx.doi.org/10.1016/j.canlet.2013.01.054] [PMID: 23402814] 
[97] 
Hassan KA, Wang L, Korkaya H, et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clinical cancer research. Official J Am Assoc Cancer Res  2013; 19: 1972-80.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-0370] 
[98] 
Razumilava N, Gores GJ. Notch-driven carcinogenesis: the merging of hepatocellular cancer and cholangiocarcinoma into a common molecular liver cancer subtype. J Hepatol  2013; 58(6): 1244-5.
[http://dx.doi.org/10.1016/j.jhep.2013.01.017] [PMID: 23352938] 
[99] 
Balint K, Xiao M, Pinnix CC, et al. Activation of notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest  2005; 115(11): 3166-76.
[http://dx.doi.org/10.1172/JCI25001] [PMID: 16239965] 
[100] 
Liu Z-J, Xiao M, Balint K, et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res  2006; 66(8): 4182-90.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-3589] [PMID: 16618740] 
[101] 
Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer  2015; 113(3): 365-71.
[http://dx.doi.org/10.1038/bjc.2015.233] [PMID: 26151455] 
[102] 
Luo N, Balko JM. Role of JAK-STAT Pathway in Cancer Signaling InPredictive Biomarkers in Oncology.  Springer Cham 2019; pp. 311-9.
[http://dx.doi.org/10.1007/978-3-319-95228-4_26] 
[103] 
Groner B, von Manstein V. Jak Stat signaling and cancer: opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol  2017; 451: 1-14.
[http://dx.doi.org/10.1016/j.mce.2017.05.033] [PMID: 28576744] 
[104] 
Verhoeven Y, Tilborghs S, Jacobs J, et al. The potential and controversy of targeting STAT family members in cancer Semin Cancer  Biol 2019; pii: S1044-579X(19)30051-3 In Press
[http://dx.doi.org/10.1016/j.semcancer.2019.10.002] [PMID: 31605750] 
[105] 
Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer  2009; 9(11): 798-809.
[http://dx.doi.org/10.1038/nrc2734] [PMID: 19851315] 
[106] 
Shahmarvand N, Nagy A, Shahryari J, Ohgami RS. Mutations in the signal transducer and activator of transcription family of genes in cancer. Cancer Sci  2018; 109(4): 926-33.
[http://dx.doi.org/10.1111/cas.13525] [PMID: 29417693] 
[107] 
Hsiao JR, Jin YT, Tsai ST, Shiau AL, Wu CL, Su WC. Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer  2003; 89(2): 344-9.
[http://dx.doi.org/10.1038/sj.bjc.6601003] [PMID: 12865928] 
[108] 
Nevalainen MT, Xie J, Torhorst J, et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol  2004; 22(11): 2053-60.
[http://dx.doi.org/10.1200/JCO.2004.11.046] [PMID: 15169792] 
[109] 
Balko JM, Schwarz LJ, Luo N, et al.  Triple-negative breast cancers
with amplification of JAK2 at the 9p24 locus demonstrate JAK2-
specific dependence. Science translational medicine 2016; 8: 334.
ra53-3.
[110] 
Zimmers TA, Fishel ML, Bonetto A. STAT3 in the systemic inflammation of cancer cachexia. Semin Cell Dev Biol  2016; 54: 28-41.
[http://dx.doi.org/10.1016/j.semcdb.2016.02.009] [PMID: 26860754] 
[111] 
Taipale J, Beachy PA. The hedgehog and Wnt signalling pathways in cancer. Nature  2001; 411(6835): 349-54.
[http://dx.doi.org/10.1038/35077219] [PMID: 11357142] 
[112] 
Murone M, Rosenthal A, de Sauvage FJ. Hedgehog signal transduction: from flies to vertebrates. Exp Cell Res  1999; 253(1): 25-33.
[http://dx.doi.org/10.1006/excr.1999.4676] [PMID: 10579908] 
[113] 
Rubin LL, de Sauvage FJ. Targeting the hedgehog pathway in cancer. Nat Rev Drug Discov  2006; 5(12): 1026-33.
[http://dx.doi.org/10.1038/nrd2086] [PMID: 17139287] 
[114] 
Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol  2005; 152(1): 43-51.
[http://dx.doi.org/10.1111/j.1365-2133.2005.06353.x] [PMID: 15656799] 
[115] 
Johnson RL, Rothman AL, Xie J, et al. Human homolog of a candidate gene for the basal cell nevus syndrome. Science  1996; 272(5268): 1668-71.
[http://dx.doi.org/10.1126/science.272.5268.1668] [PMID: 8658145] 
[116] 
Vorechovský I, Undén AB, Sandstedt B, Toftgård R, Ståhle-Bäckdahl M. Trichoepitheliomas contain somatic mutations in the overexpressed PTCH gene: support for a gatekeeper mechanism in skin tumorigenesis. Cancer Res  1997; 57(21): 4677-81.
[PMID: 9354420] 
[117] 
McGarvey TW, Maruta Y, Tomaszewski JE, Linnenbach AJ, Malkowicz SB. PTCH gene mutations in invasive transitional cell carcinoma of the bladder. Oncogene  1998; 17(9): 1167-72.
[http://dx.doi.org/10.1038/sj.onc.1202045] [PMID: 9764827] 
[118] 
Maesawa C, Tamura G, Iwaya T, et al. Mutations in the human homologue of the drosophila patched gene in esophageal squamous cell carcinoma. Genes Chromosomes Cancer  1998; 21(3): 276-9.
[http://dx.doi.org/10.1002/(SICI)1098-2264(199803)21:3<276:AID-GCC15>3.0.CO;2-N] [PMID: 9523206] 
[119] 
Almazán-Moga A, Zarzosa P, Molist C, et al. Ligand-dependent hedgehog pathway activation in rhabdomyosarcoma: the oncogenic role of the ligands. Br J Cancer  2017; 117(9): 1314-25.
[http://dx.doi.org/10.1038/bjc.2017.305] [PMID: 28881358] 
[120] 
Smyth I, Narang MA, Evans T, et al. Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Hum Mol Genet  1999; 8(2): 291-7.
[http://dx.doi.org/10.1093/hmg/8.2.291] [PMID: 9931336] 
[121] 
Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumours. Nature  2003; 425(6960): 846-51.
[http://dx.doi.org/10.1038/nature01972] [PMID: 14520411] 
[122] 
Gulino A, Ferretti E, De Smaele E. Hedgehog signalling in colon cancer and stem cells. EMBO Mol Med  2009; 1(6-7): 300-2.
[http://dx.doi.org/10.1002/emmm.200900042] [PMID: 20049733] 
[123] 
Szkandera J, Kiesslich T, Haybaeck J, Gerger A, Pichler M. Hedgehog signaling pathway in ovarian cancer. Int J Mol Sci  2013; 14(1): 1179-96.
[http://dx.doi.org/10.3390/ijms14011179] [PMID: 23303278] 
[124] 
Kubo M, Nakamura M, Tasaki A, et al. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res  2004; 64(17): 6071-4.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-0416] [PMID: 15342389] 
[125] 
Sheng T, Li C, Zhang X, et al. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer  2004; 3: 29.
[http://dx.doi.org/10.1186/1476-4598-3-29] [PMID: 15482598] 
[126] 
Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature  2003; 422(6929): 313-7.
[http://dx.doi.org/10.1038/nature01493] [PMID: 12629553] 
[127] 
O’Reilly KE, de Miera EV, Segura MF, et al. Hedgehog pathway blockade inhibits melanoma cell growth in vitro and in vivo. Pharmaceuticals (Basel)  2013; 6(11): 1429-50.
[http://dx.doi.org/10.3390/ph6111429] [PMID: 24287465] 
[128] 
Becher OJ, Hambardzumyan D, Fomchenko EI, et al. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res  2008; 68(7): 2241-9.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-6350] [PMID: 18381430] 
[129] 
Monzo M, Moreno I, Artells R, et al. Sonic hedgehog mRNA expression by real-time quantitative PCR in normal and tumor tissues from colorectal cancer patients. Cancer Lett  2006; 233(1): 117-23.
[http://dx.doi.org/10.1016/j.canlet.2005.03.001] [PMID: 16473672] 
[130] 
Douard R, Moutereau S, Pernet P, et al. Sonic Hedgehog-dependent proliferation in a series of patients with colorectal cancer. Surgery  2006; 139(5): 665-70.
[http://dx.doi.org/10.1016/j.surg.2005.10.012] [PMID: 16701100] 
[131] 
van den Brink GR, Bleuming SA, Hardwick JCH, et al. Indian hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation. Nat Genet  2004; 36(3): 277-82.
[http://dx.doi.org/10.1038/ng1304] [PMID: 14770182] 
[132] 
Akiyoshi T, Nakamura M, Koga K, et al. Gli1, downregulated in colorectal cancers, inhibits proliferation of colon cancer cells involving Wnt signalling activation. Gut  2006; 55(7): 991-9.
[http://dx.doi.org/10.1136/gut.2005.080333] [PMID: 16299030] 
[133] 
Fan L, Pepicelli CV, Dibble CC, et al. Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology  2004; 145(8): 3961-70.
[http://dx.doi.org/10.1210/en.2004-0079] [PMID: 15132968] 
[134] 
Theunissen J-W, de Sauvage FJ. Paracrine Hedgehog signaling in cancer. Cancer Res  2009; 69(15): 6007-10.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-0756] [PMID: 19638582] 
[135] 
Skoda AM, Simovic D, Karin V, Kardum V, Vranic S, Serman L. The role of the hedgehog signaling pathway in cancer: A comprehensive review. Bosn J Basic Med Sci  2018; 18(1): 8-20.
[http://dx.doi.org/10.17305/bjbms.2018.2756] [PMID: 29274272] 
[136] 
Lai S-L, Chien AJ, Moon RT. Wnt/Fz signaling and the cytoskeleton: potential roles in tumorigenesis. Cell Res  2009; 19(5): 532-45.
[http://dx.doi.org/10.1038/cr.2009.41] [PMID: 19365405] 
[137] 
Yamamoto S, Nishimura O, Misaki K, et al. Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex. Dev Cell  2008; 15(1): 23-36.
[http://dx.doi.org/10.1016/j.devcel.2008.05.007] [PMID: 18606138] 
[138] 
van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development  2009; 136(19): 3205-14.
[http://dx.doi.org/10.1242/dev.033910] [PMID: 19736321] 
[139] 
Duchartre Y, Kim Y-M, Kahn M. The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol  2016; 99: 141-9.
[http://dx.doi.org/10.1016/j.critrevonc.2015.12.005] [PMID: 26775730] 
[140] 
Katoh M. Expression and regulation of WNT1 in human cancer: up-regulation of WNT1 by beta-estradiol in MCF-7 cells. Int J Oncol  2003; 22(1): 209-12.
[http://dx.doi.org/10.3892/ijo.22.1.209] [PMID: 12469206] 
[141] 
You L, He B, Xu Z, et al. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene  2004; 23(36): 6170-4.
[http://dx.doi.org/10.1038/sj.onc.1207844] [PMID: 15208662] 
[142] 
Katoh M, Kirikoshi H, Terasaki H, Shiokawa K. WNT2B2 mRNA, up-regulated in primary gastric cancer, is a positive regulator of the WNT- β-catenin-TCF signaling pathway. Biochem Biophys Res Commun  2001; 289(5): 1093-8.
[http://dx.doi.org/10.1006/bbrc.2001.6076] [PMID: 11741304] 
[143] 
Verras M, Brown J, Li X, Nusse R, Sun Z. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res  2004; 64(24): 8860-6.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-2370] [PMID: 15604245] 
[144] 
Flanagan D, Barker NS, Di Costanzo N, et al. Frizzled-7 is required for Wnt Signaling in gastric tumors with and without apc mutations. Cancer Res  2019; 79.
[145] 
Terasaki H, Saitoh T, Shiokawa K, Katoh M. Frizzled-10, up-regulated in primary colorectal cancer, is a positive regulator of the WNT - β-catenin - TCF signaling pathway. Int J Mol Med  2002; 9(2): 107-12.
[http://dx.doi.org/10.3892/ijmm.9.2.107] [PMID: 11786918] 
[146] 
Okino K, Nagai H, Hatta M, et al. Up-regulation and overproduction of DVL-1, the human counterpart of the drosophila dishevelled gene, in cervical squamous cell carcinoma. Oncol Rep  2003; 10(5): 1219-23.
[http://dx.doi.org/10.3892/or.10.5.1219] [PMID: 12883684] 
[147] 
Uematsu K, Kanazawa S, You L, et al. Wnt pathway activation in mesothelioma: evidence of dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res  2003; 63(15): 4547-51.
[PMID: 12907630] 
[148] 
Suzuki H, Watkins DN, Jair K-W, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet  2004; 36(4): 417-22.
[http://dx.doi.org/10.1038/ng1330] [PMID: 15034581] 
[149] 
Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer  2006; 6(2): 107-16.
[http://dx.doi.org/10.1038/nrc1799] [PMID: 16491070] 
[150] 
Ying Y, Tao Q.  Epigenetic disruption of the WNT/beta-catenin
signaling pathway in human cancers 2009; 4(5): 307-12.
[151] 
Saitoh T, Mine T, Katoh M. Frequent up-regulation of WNT5A mRNA in primary gastric cancer. Int J Mol Med  2002; 9(5): 515-9.
[http://dx.doi.org/10.3892/ijmm.9.5.515] [PMID: 11956659] 
[152] 
Vider BZ, Zimber A, Chastre E, et al. Evidence for the involvement of the Wnt 2 gene in human colorectal cancer. Oncogene  1996; 12(1): 153-8.
[PMID: 8552386] 
[153] 
Huang CL, Liu D, Nakano J, et al. Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor-an expression in non-small-cell lung cancer. J Clin Oncol  2005; 23(34): 8765-73.
[http://dx.doi.org/10.1200/JCO.2005.02.2871] [PMID: 16314637] 
[154] 
Ying J, Li H, Chen Y-W, Srivastava G, Gao Z, Tao Q. WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor. Blood  2007; 110(12): 4130-2.
[http://dx.doi.org/10.1182/blood-2007-06-094870] [PMID: 18024799] 
[155] 
Liang H, Chen Q, Coles AH, et al. Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell  2003; 4(5): 349-60.
[http://dx.doi.org/10.1016/S1535-6108(03)00268-X] [PMID: 14667502] 
[156] 
Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res  2003; 63(13): 3735-42.
[PMID: 12839967] 
[157] 
Shu J, Jelinek J, Chang H, et al. Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res  2006; 66(10): 5077-84.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-2629] [PMID: 16707430] 
[158] 
Chan SL, Cui Y, van Hasselt A, et al. The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. Lab Invest  2007; 87(7): 644-50.
[http://dx.doi.org/10.1038/labinvest.3700547] [PMID: 17384664] 
[159] 
Taniguchi H, Yamamoto H, Hirata T, et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene  2005; 24(53): 7946-52.
[http://dx.doi.org/10.1038/sj.onc.1208910] [PMID: 16007117] 
[160] 
Mazieres J, He B, You L, et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res  2004; 64(14): 4717-20.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-1389] [PMID: 15256437] 
[161] 
Román-Gómez J, Cordeu L, Agirre X, et al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood  2007; 109(8): 3462-9.
[http://dx.doi.org/10.1182/blood-2006-09-047043] [PMID: 17148581] 
[162] 
Sato H, Suzuki H, Toyota M, et al. Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis  2007; 28(12): 2459-66.
[http://dx.doi.org/10.1093/carcin/bgm178] [PMID: 17675336] 
[163] 
Urakami S, Shiina H, Enokida H, et al. 770: Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder carcinogenesis through aberrant Wnt signaling activation. J Urol  2005; 173: 209.
[http://dx.doi.org/10.1016/S0022-5347(18)34939-5] 
[164] 
Zhang W, Glöckner SC, Guo M, et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res  2008; 68(8): 2764-72.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-6349] [PMID: 18413743] 
[165] 
Fu D-Y, Wang Z-M. Li-Chen , et al Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat  2010; 119(3): 601-12.
[http://dx.doi.org/10.1007/s10549-009-0339-8] [PMID: 19301122] 
[166] 
Prasad CP, Mirza S, Sharma G, et al. Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/β-catenin pathway in invasive ductal carcinoma of breast. Life Sci  2008; 83(9-10): 318-25.
[http://dx.doi.org/10.1016/j.lfs.2008.06.019] [PMID: 18662704] 
[167] 
Wheeler JM, Kim HC, Efstathiou JA, Ilyas M, Mortensen NJ, Bodmer WF. Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer. Gut  2001; 48(3): 367-71.
[http://dx.doi.org/10.1136/gut.48.3.367] [PMID: 11171827] 
[168] 
Loss of E-cadherin
expression in gastric intestinal metaplasia and later stage p53 altered
expression in gastric carcinogenesis. Exp Toxicol Pathol
2001; 53(4): 237-46. 
[http://dx.doi.org/10.1078/0940-2993-00190] [PMID: 11665847] 
[169] 
Karin M, Cao Y, Greten FR, Li Z-W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer  2002; 2(4): 301-10.
[http://dx.doi.org/10.1038/nrc780] [PMID: 12001991] 
[170] 
Nakajima S, Kitamura M. Bidirectional regulation of NF-κB by reactive oxygen species: a role of unfolded protein response. Free Radic Biol Med  2013; 65: 162-74.
[http://dx.doi.org/10.1016/j.freeradbiomed.2013.06.020] [PMID: 23792277] 
[171] 
Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest  2001; 107(1): 7-11.
[http://dx.doi.org/10.1172/JCI11830] [PMID: 11134171] 
[172] 
Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol  1994; 12: 141-79.
[http://dx.doi.org/10.1146/annurev.iy.12.040194.001041] [PMID: 8011280] 
[173] 
Park MH, Hong JT. Roles of NF-κB in cancer and inflammatory diseases and their therapeutic approaches. Cells  2016; 5(2): 15.
[http://dx.doi.org/10.3390/cells5020015] [PMID: 27043634] 
[174] 
Nelson DE, Ihekwaba AEC, Elliott M, et al. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science  2004; 306(5696): 704-8.
[http://dx.doi.org/10.1126/science.1099962] [PMID: 15499023] 
[175] 
Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev  2010; 29(3): 405-34.
[http://dx.doi.org/10.1007/s10555-010-9235-2] [PMID: 20737283] 
[176] 
Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem  2010; 336(1-2): 25-37.
[http://dx.doi.org/10.1007/s11010-009-0267-2] [PMID: 19823771] 
[177] 
Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[κ]B activity. Annu Rev Immunol  2000; 18: 621-63.
[http://dx.doi.org/10.1146/annurev.immunol.18.1.621] [PMID: 10837071] 
[178] 
Tilstra JS, Clauson CL, Niedernhofer LJ, Robbins PD. NF-κB in aging and disease. Aging Dis  2011; 2(6): 449-65.
[PMID: 22396894] 
[179] 
Sovak MA, Bellas RE, Kim DW, et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest  1997; 100(12): 2952-60.
[http://dx.doi.org/10.1172/JCI119848] [PMID: 9399940] 
[180] 
Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol  1997; 17(7): 3629-39.
[http://dx.doi.org/10.1128/MCB.17.7.3629] [PMID: 9199297] 
[181] 
Lind DS, Hochwald SN, Malaty J, et al. Nuclear factor-κ B is upregulated in colorectal cancer. Surgery  2001; 130(2): 363-9.
[http://dx.doi.org/10.1067/msy.2001.116672] [PMID: 11490372] 
[182] 
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell  2010; 140(6): 883-99.
[http://dx.doi.org/10.1016/j.cell.2010.01.025] [PMID: 20303878] 
[183] 
Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-α-induced cell death. Science  1996; 274(5288): 782-4.
[http://dx.doi.org/10.1126/science.274.5288.782] [PMID: 8864118] 
[184] 
Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-kappaB. Science  1996; 274(5288): 787-9.
[http://dx.doi.org/10.1126/science.274.5288.787] [PMID: 8864120] 
[185] 
Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol  2002; 3(3): 221-7.
[http://dx.doi.org/10.1038/ni0302-221] [PMID: 11875461] 
[186] 
Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev  2010; 233(1): 233-55.
[http://dx.doi.org/10.1111/j.0105-2896.2009.00859.x] [PMID: 20193003] 
[187] 
Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep  2014; 15(12): 1243-53.
[http://dx.doi.org/10.15252/embr.201439246] [PMID: 25381661] 
[188] 
Lane BR, Liu J, Bock PJ, et al. Interleukin-8 and growth-regulated oncogene alpha mediate angiogenesis in Kaposi’s sarcoma. J Virol  2002; 76(22): 11570-83.
[http://dx.doi.org/10.1128/JVI.76.22.11570-11583.2002] [PMID: 12388718] 
[189] 
Escárcega RO, Fuentes-Alexandro S, García-Carrasco M, Gatica A, Zamora A. The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol)  2007; 19(2): 154-61.
[http://dx.doi.org/10.1016/j.clon.2006.11.013] [PMID: 17355113] 
[190] 
Yu S, Sun L, Jiao Y, Lee LTO. The role of G protein-coupled receptor kinases in cancer. Int J Biol Sci  2018; 14(2): 189-203.
[http://dx.doi.org/10.7150/ijbs.22896] [PMID: 29483837] 
[191] 
Katritch V, Cherezov V, Stevens RC. Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol  2013; 53: 531-56.
[http://dx.doi.org/10.1146/annurev-pharmtox-032112-135923] [PMID: 23140243] 
[192] 
Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. Molecular signatures of G-protein-coupled receptors. Nature  2013; 494(7436): 185-94.
[http://dx.doi.org/10.1038/nature11896] [PMID: 23407534] 
[193] 
Hurowitz EH, Melnyk JM, Chen Y-J, Kouros-Mehr H, Simon MI, Shizuya H. Genomic characterization of the human heterotrimeric G protein α, β, and γ subunit genes. DNA Res  2000; 7(2): 111-20.
[http://dx.doi.org/10.1093/dnares/7.2.111] [PMID: 10819326] 
[194] 
Wang D. The essential role of G protein-coupled receptor (GPCR) signaling in regulating T cell immunity. Immunopharmacol Immunotoxicol  2018; 40(3): 187-92.
[http://dx.doi.org/10.1080/08923973.2018.1434792] [PMID: 29433403] 
[195] 
Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol  2002; 3(9): 639-50.
[http://dx.doi.org/10.1038/nrm908] [PMID: 12209124] 
[196] 
Neves SR, Ram PT, Iyengar R. G protein pathways. Science  2002; 296(5573): 1636-9.
[http://dx.doi.org/10.1126/science.1071550] [PMID: 12040175] 
[197] 
Wiley SZ, Sriram K, Salmerón C, Insel PA. GPR68: an emerging drug target in cancer. Int J Mol Sci  2019; 20(3): 559.
[http://dx.doi.org/10.3390/ijms20030559] [PMID: 30696114] 
[198] 
Wiley SZ, Sriram K, Liang W, et al. GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. FASEB J  2018; 32(3): 1170-83.
[http://dx.doi.org/10.1096/fj.201700834R] [PMID: 29092903] 
[199] 
Horman SR, To J, Lamb J, et al. Functional profiling of microtumors to identify cancer associated fibroblast-derived drug targets. Oncotarget  2017; 8(59): 99913-30.
[http://dx.doi.org/10.18632/oncotarget.21915] [PMID: 29245949] 
[200] 
Wei W-C, Huang W-C, Lin Y-P, et al. Functional expression of calcium-permeable canonical transient receptor potential 4-containing channels promotes migration of medulloblastoma cells. J Physiol  2017; 595(16): 5525-44.
[http://dx.doi.org/10.1113/JP274659] [PMID: 28627017] 
[201] 
LaTulippe E, Satagopan J, Smith A, et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res  2002; 62(15): 4499-506.
[PMID: 12154061] 
[202] 
Singh LS, Berk M, Oates R, et al. Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer. J Natl Cancer Inst  2007; 99(17): 1313-27.
[http://dx.doi.org/10.1093/jnci/djm107] [PMID: 17728215] 
[203] 
Ren J, Zhang L. Effects of ovarian cancer G protein coupled receptor 1 on the proliferation, migration, and adhesion of human ovarian cancer cells. Chin Med J (Engl)  2011; 124(9): 1327-32.
[PMID: 21740742] 
[204] 
Yan L, Singh LS, Zhang L, Xu Y. Role of OGR1 in myeloid-derived cells in prostate cancer. Oncogene  2014; 33(2): 157-64.
[http://dx.doi.org/10.1038/onc.2012.566] [PMID: 23222714] 
[205] 
Miller E, Yang J, DeRan M, et al. Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. Chem Biol  2012; 19(8): 955-62.
[http://dx.doi.org/10.1016/j.chembiol.2012.07.005] [PMID: 22884261] 
[206] 
Mo J-S, Yu F-X, Gong R, Brown JH, Guan K-L. Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev  2012; 26(19): 2138-43.
[http://dx.doi.org/10.1101/gad.197582.112] [PMID: 22972936] 
[207] 
Moya IM, Halder G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol  2019; 20(4): 211-26.
[http://dx.doi.org/10.1038/s41580-018-0086-y] [PMID: 30546055] 
[208] 
Boopathy GTK, Hong W. Role of hippo pathway-YAP/TAZ signaling in angiogenesis. Front Cell Dev Biol  2019; 7: 49.
[http://dx.doi.org/10.3389/fcell.2019.00049] [PMID: 31024911] 
[209] 
Bar-Shavit R, Maoz M, Kancharla A, et al. G protein-coupled receptors in cancer. Int J Mol Sci  2016; 17(8): 1320.
[http://dx.doi.org/10.3390/ijms17081320] [PMID: 27529230] 
[210] 
Han Y. Analysis of the role of the hippo pathway in cancer. J Transl Med  2019; 17(1): 116-6.
[http://dx.doi.org/10.1186/s12967-019-1869-4] [PMID: 30961610] 
[211] 
Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell  2016; 29(6): 783-803.
[http://dx.doi.org/10.1016/j.ccell.2016.05.005] [PMID: 27300434] 
[212] 
Zhao B, Ye X, Yu J, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev  2008; 22(14): 1962-71.
[http://dx.doi.org/10.1101/gad.1664408] [PMID: 18579750] 
[213] 
Holden JK, Cunningham CN. Targeting the hippo pathway and cancer through the TEAD family of transcription factors. Cancers (Basel)  2018; 10(3): 81.
[http://dx.doi.org/10.3390/cancers10030081] [PMID: 29558384] 
[214] 
Yu F-X, Zhao B, Panupinthu N, et al. Regulation of the hippo-YAP pathway by G-protein-coupled receptor signaling. Cell  2012; 150(4): 780-91.
[http://dx.doi.org/10.1016/j.cell.2012.06.037] [PMID: 22863277] 
[215] 
Yu F-X, Luo J, Mo J-S, et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell  2014; 25(6): 822-30.
[http://dx.doi.org/10.1016/j.ccr.2014.04.017] [PMID: 24882516] 
[216] 
Pan D. The hippo signaling pathway in development and cancer. Dev Cell  2010; 19(4): 491-505.
[http://dx.doi.org/10.1016/j.devcel.2010.09.011] [PMID: 20951342] 
[217] 
Yu F-X, Zhang Y, Park HW, et al. Protein kinase a activates the hippo pathway to modulate cell proliferation and differentiation. Genes Dev  2013; 27(11): 1223-32.
[http://dx.doi.org/10.1101/gad.219402.113] [PMID: 23752589] 
[218] 
Ramos A, Camargo FD. The hippo signaling pathway and stem cell biology. Trends Cell Biol  2012; 22(7): 339-46.
[http://dx.doi.org/10.1016/j.tcb.2012.04.006] [PMID: 22658639] 
[219] 
Zhao B, Li L, Lei Q, Guan K-L. The hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev  2010; 24(9): 862-74.
[http://dx.doi.org/10.1101/gad.1909210] [PMID: 20439427] 
[220] 
Sudol M, Bork P, Einbond A, et al. Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain. J Biol Chem  1995; 270(24): 14733-41.
[http://dx.doi.org/10.1074/jbc.270.24.14733] [PMID: 7782338] 
[221] 
Feng X, Degese MS, Iglesias-Bartolome R, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell  2014; 25(6): 831-45.
[http://dx.doi.org/10.1016/j.ccr.2014.04.016] [PMID: 24882515	] 
[222] 
Park HW, Kim YC, Yu B, et al. Alternative Wnt signaling activates YAP/TAZ. Cell  2015; 162(4): 780-94.
[http://dx.doi.org/10.1016/j.cell.2015.07.013] [PMID: 26276632] 
[223] 
Fuchs SY, Adler V, Pincus MR, Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA  1998; 95(18): 10541-6.
[http://dx.doi.org/10.1073/pnas.95.18.10541] [PMID: 9724739] 
[224] 
Fuchs SY, Dolan L, Davis RJ, Ronai Z. Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase. Oncogene  1996; 13(7): 1531-5.
[PMID: 8875991] 
[225] 
Fuchs SY, Xie B, Adler V, Fried VA, Davis RJ, Ronai Z. c-Jun NH2-terminal kinases target the ubiquitination of their associated transcription factors. J Biol Chem  1997; 272(51): 32163-8.
[http://dx.doi.org/10.1074/jbc.272.51.32163] [PMID: 9405416] 
[226] 
Musti AM, Treier M, Bohmann D. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science  1997; 275(5298): 400-2.
[http://dx.doi.org/10.1126/science.275.5298.400] [PMID: 8994040] 
[227] 
Liu K-Q, Liu Z-P, Hao J-K, Chen L, Zhao X-M. Identifying dysregulated pathways in cancers from pathway interaction networks. BMC Bioinformatics  2012; 13: 126-6.
[http://dx.doi.org/10.1186/1471-2105-13-126] [PMID: 22676414] 
[228] 
English JM, Cobb MH. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci  2002; 23(1): 40-5.
[http://dx.doi.org/10.1016/S0165-6147(00)01865-4] [PMID: 11804650] 
[229] 
Park J-I, Lee M-G, Cho K, et al. Transforming growth factor-β1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene  2003; 22(28): 4314-32.
[http://dx.doi.org/10.1038/sj.onc.1206478] [PMID: 12853969] 
[230] 
Khandrika L, Lieberman R, Koul S, et al. Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1α levels contribute to emergence of an aggressive phenotype in prostate cancer. Oncogene  2009; 28(9): 1248-60.
[http://dx.doi.org/10.1038/onc.2008.476] [PMID: 19151763] 
[231] 
Maroni PD, Koul S, Meacham RB, Koul HK. Mitogen activated protein kinase signal transduction pathways in the prostate. Cell Commun Signal  2004; 2(1): 5-5.
[http://dx.doi.org/10.1186/1478-811X-2-5] [PMID: 15219238] 
[232] 
Tsai P-W, Shiah S-G, Lin M-T, Wu C-W, Kuo M-L. Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-β 1. A critical role of p38/nuclear factor-κ B signaling pathway. J Biol Chem  2003; 278(8): 5750-9.
[http://dx.doi.org/10.1074/jbc.M204863200] [PMID: 12471041] 
[233] 
Suarez-Cuervo C, Merrell MA, Watson L, et al. Breast cancer cells with inhibition of p38α have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis  2004; 21(6): 525-33.
[http://dx.doi.org/10.1007/s10585-004-3503-x] [PMID: 15679050] 
[234] 
Kumar B, Koul S, Petersen J, et al. p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res  2010; 70(2): 832-41.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-2918] [PMID: 20068172] 
[235] 
Iyoda K, Sasaki Y, Horimoto M, et al. Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer  2003; 97(12): 3017-26.
[http://dx.doi.org/10.1002/cncr.11425] [PMID: 12784337] 
[236] 
Greenberg AK, Basu S, Hu J, et al. Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol  2002; 26(5): 558-64.
[http://dx.doi.org/10.1165/ajrcmb.26.5.4689] [PMID: 11970907] 
[237] 
Elenitoba-Johnson KSJ, Jenson SD, Abbott RT, et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci USA  2003; 100(12): 7259-64.
[http://dx.doi.org/10.1073/pnas.1137463100] [PMID: 12756297] 
[238] 
Lin Z, Crockett DK, Jenson SD, Lim MS, Elenitoba-Johnson KSJ. Quantitative proteomic and transcriptional analysis of the response to the p38 mitogen-activated protein kinase inhibitor SB203580 in transformed follicular lymphoma cells. Mol Cell Proteomics  2004; 3(8): 820-33.
[http://dx.doi.org/10.1074/mcp.M400008-MCP200] [PMID: 15169874] 
[239] 
Bhowmick NA, Ghiassi M, Bakin A, et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell  2001; 12(1): 27-36.
[http://dx.doi.org/10.1091/mbc.12.1.27] [PMID: 11160820] 
[240] 
Bhowmick NA, Zent R, Ghiassi M, McDonnell M, Moses HL. Integrin β 1 signaling is necessary for transforming growth factor-β activation of p38MAPK and epithelial plasticity. J Biol Chem  2001; 276(50): 46707-13.
[http://dx.doi.org/10.1074/jbc.M106176200] [PMID: 11590169] 
[241] 
Sosa MS, Avivar-Valderas A, Bragado P, Wen H-C, Aguirre-Ghiso JA. ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin Cancer Research. Official J Am Assoc Cancer Research  2011; 17: 5850-7.
[242] 
Cheng Y, Qiu F, Tashiro S, Onodera S, Ikejima T. ERK and JNK mediate TNFalpha-induced p53 activation in apoptotic and autophagic L929 cell death. Biochem Biophys Res Commun  2008; 376(3): 483-8.
[http://dx.doi.org/10.1016/j.bbrc.2008.09.018] [PMID: 18796294] 
[243] 
Cheng T-L, Symons M, Jou T-S. Regulation of anoikis by Cdc42 and Rac1. Exp Cell Res  2004; 295(2): 497-511.
[http://dx.doi.org/10.1016/j.yexcr.2004.02.002] [PMID: 15093747] 
[244] 
Ellinger-Ziegelbauer H, Kelly K, Siebenlist U. Cell cycle arrest and reversion of Ras-induced transformation by a conditionally activated form of mitogen-activated protein kinase kinase kinase 3. Mol Cell Biol  1999; 19(5): 3857-68.
[http://dx.doi.org/10.1128/MCB.19.5.3857] [PMID: 10207109] 
[245] 
Pruitt K, Pruitt WM, Bilter GK, Westwick JK, Der CJ. Raf-independent deregulation of p38 and JNK mitogen-activated protein kinases are critical for Ras transformation. J Biol Chem  2002; 277(35): 31808-17.
[http://dx.doi.org/10.1074/jbc.M203964200] [PMID: 12082106	] 
[246] 
Bulavin DV, Fornace AJ.  p38 MAP kinase's emerging role as a
tumor suppressor. Adv Cancer Res. Academic Press 2004; (92): 95-
118.
[247] 
Kummer JL, Rao PK, Heidenreich KA. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem  1997; 272(33): 20490-4.
[http://dx.doi.org/10.1074/jbc.272.33.20490] [PMID: 9252360] 
[248] 
She Q-B, Bode AM, Ma W-Y, Chen N-Y, Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res  2001; 61(4): 1604-10.
[PMID: 11245472] 
[249] 
Bradham C, McClay DR. p38 MAPK in development and cancer. Cell Cycle  2006; 5(8): 824-8.
[http://dx.doi.org/10.4161/cc.5.8.2685] [PMID: 16627995] 
[250] 
Bulavin DV, Demidov ON, Saito S, et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet  2002; 31(2): 210-5.
[http://dx.doi.org/10.1038/ng894] [PMID: 12021785] 
[251] 
Brancho D, Tanaka N, Jaeschke A, et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev  2003; 17(16): 1969-78.
[http://dx.doi.org/10.1101/gad.1107303] [PMID: 12893778] 
[252] 
Timofeev O, Lee TY, Bulavin DV. A subtle change in p38 MAPK activity is sufficient to suppress in vivo tumorigenesis. Cell Cycle  2005; 4(1): 118-20.
[http://dx.doi.org/10.4161/cc.4.1.1342] [PMID: 15611662] 
[253] 
Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer  2013; 4(9-10): 342-59.
[http://dx.doi.org/10.1177/1947601913507951] [PMID: 24349632] 
[254] 
Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer  2009; 9(10): 749-58.
[http://dx.doi.org/10.1038/nrc2723] [PMID: 19776744] 
[255] 
Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell  1992; 69(7): 1237-45.
[http://dx.doi.org/10.1016/0092-8674(92)90644-R] [PMID: 1535557] 
[256] 
Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J  1993; 12(2): 461-8.
[http://dx.doi.org/10.1002/j.1460-2075.1993.tb05678.x] [PMID: 8440237] 
[257] 
Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev  2010; 24(15): 1580-9.
[http://dx.doi.org/10.1101/gad.1941710] [PMID: 20679392] 
[258] 
Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol  2010; 20(5): 299-309.
[http://dx.doi.org/10.1016/j.tcb.2010.01.009] [PMID: 20172729] 
[259] 
Mendoza M, Mandani G, Momand J. The MDM2 gene family. Biomol Concepts  2014; 5(1): 9-19.
[http://dx.doi.org/10.1515/bmc-2013-0027] [PMID: 25372739] 
[260] 
Mandinova A, Lee SW. The p53 pathway as a target in cancer therapeutics: obstacles and promise  Science translational medicine
2011; 3: 64. rv1.
[http://dx.doi.org/10.1126/scitranslmed.3001366] 
[261] 
Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ  2006; 13(6): 951-61.
[http://dx.doi.org/10.1038/sj.cdd.4401916] [PMID: 16575405] 
[262] 
Kruse J-P, Gu W. Modes of p53 regulation. Cell  2009; 137(4): 609-22.
[http://dx.doi.org/10.1016/j.cell.2009.04.050] [PMID: 19450511] 
[263] 
Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res  2002; 4(2): 70-6.
[http://dx.doi.org/10.1186/bcr426] [PMID: 11879567] 
[264] 
Slattery ML, Mullany LE, Wolff RK, Sakoda LC, Samowitz WS, Herrick JS. The p53-signaling pathway and colorectal cancer: Interactions between downstream p53 target genes and miRNAs. Genomics  2019; 111(4): 762-71.
[http://dx.doi.org/10.1016/j.ygeno.2018.05.006] [PMID: 29860032] 
[265] 
Xiang J-F, Wang W-Q, Liu L, et al. Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9≥1,000U/mL. Sci Rep  2016; 6: 19222.
[http://dx.doi.org/10.1038/srep19222] [PMID: 26753987] 
[266] 
Corney DC, Flesken-Nikitin A, Choi J, Nikitin AY. Role of p53 and Rb in ovarian cancer. Adv Exp Med Biol  2008; 622: 99-117.
[http://dx.doi.org/10.1007/978-0-387-68969-2_9] [PMID: 18546622] 
[267] 
Gibbons DL, Byers LA, Kurie JM. Smoking, p53 mutation, and lung cancer. Mol Cancer Res  2014; 12(1): 3-13.
[http://dx.doi.org/10.1158/1541-7786.MCR-13-0539] [PMID: 24442106] 
[268] 
Gasco M, Crook T. The p53 network in head and neck cancer. Oral Oncol  2003; 39(3): 222-31.
[http://dx.doi.org/10.1016/S1368-8375(02)00163-X] [PMID: 12618194] 
[269] 
Jiménez C, Portela RA, Mellado M, et al. Role of the PI3K regulatory subunit in the control of actin organization and cell migration. J Cell Biol  2000; 151(2): 249-62.
[http://dx.doi.org/10.1083/jcb.151.2.249] [PMID: 11038173] 
[270] 
Jin L, Zhou Y. Crucial role of the pentose phosphate pathway in malignant tumors. Oncol Lett  2019; 17(5): 4213-21.
[http://dx.doi.org/10.3892/ol.2019.10112] [PMID: 30944616] 
[271] 
Cho ES, Cha YH, Kim HS, Kim NH, Yook JI. The pentose phosphate pathway as a potential target for cancer therapy. Biomol Ther (Seoul)  2018; 26(1): 29-38.
[http://dx.doi.org/10.4062/biomolther.2017.179] [PMID: 29212304] 
[272] 
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science  2009; 324(5930): 1029-33.
[http://dx.doi.org/10.1126/science.1160809] [PMID: 19460998] 
[273] 
Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol  2017; 14(1): 11-31.
[http://dx.doi.org/10.1038/nrclinonc.2016.60] [PMID: 27141887] 
[274] 
Lu M, Lu L, Dong Q, et al. Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition. Acta Biochim Biophys Sin (Shanghai)  2018; 50(4): 370-80.
[http://dx.doi.org/10.1093/abbs/gmy009] [PMID: 29471502] 
[275] 
DeWaal D, Nogueira V, Terry AR, et al. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat Commun  2018; 9(1): 446-6.
[http://dx.doi.org/10.1038/s41467-017-02733-4] [PMID: 29386513] 
[276] 
Dong T, Kang X, Liu Z, et al. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer. Tumour Biol  2016; 37(6): 8159-68.
[http://dx.doi.org/10.1007/s13277-015-4729-8] [PMID: 26715276] 
[277] 
Pu H, Zhang Q, Zhao C, et al. Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression-free survival in primary breast carcinoma. World J Surg Oncol  2015; 13: 323-.
[http://dx.doi.org/10.1186/s12957-015-0733-0] [PMID: 26607846] 
[278] 
Benito A, Polat IH, Noé V, Ciudad CJ, Marin S, Cascante M. Glucose-6-phosphate dehydrogenase and transketolase modulate breast cancer cell metabolic reprogramming and correlate with poor patient outcome. Oncotarget  2017; 8(63): 106693-706.
[http://dx.doi.org/10.18632/oncotarget.21601] [PMID: 29290982] 
[279] 
Yang X, Peng X, Huang J. Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation. Clin Transl Oncol  2018; 20(9): 1145-52.
[http://dx.doi.org/10.1007/s12094-018-1833-4] [PMID: 29340974] 
[280] 
Giatromanolaki A, Sivridis E, Arelaki S, Koukourakis MI. Expression of enzymes related to glucose metabolism in non-small cell lung cancer and prognosis. Exp Lung Res  2017; 43(4-5): 167-74.
[http://dx.doi.org/10.1080/01902148.2017.1328714] [PMID: 28644754] 
[281] 
Hong W, Cai P, Xu C, et al. Inhibition of glucose-6-phosphate dehydrogenase reverses cisplatin resistance in lung cancer cells via the redox system. Front Pharmacol  2018; 9: 43-3.
[http://dx.doi.org/10.3389/fphar.2018.00043] [PMID: 29445340] 
[282] 
Zheng W, Feng Q, Liu J, et al. Inhibition of 6-phosphogluconate dehydrogenase reverses cisplatin resistance in ovarian and lung cancer. Front Pharmacol  2017; 8: 421-1.
[http://dx.doi.org/10.3389/fphar.2017.00421] [PMID: 28713273] 
[283] 
Chan B, VanderLaan PA, Sukhatme VP. 6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met. Biochem Biophys Res Commun  2013; 439(2): 247-51.
[http://dx.doi.org/10.1016/j.bbrc.2013.08.048] [PMID: 23973484] 
[284] 
Marbaniang C, Kma L. Dysregulation of glucose metabolism by oncogenes and tumor suppressors in cancer cells. Asian Pac J Cancer Prev  2018; 19(9): 2377-90.
[PMID: 30255690] 
[285] 
Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res  2012; 18(20): 5546-53.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-0977] [PMID: 23071356] 
[286] 
Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res  2009; 15(21): 6479-83.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-0889] [PMID: 19861459] 
[287] 
Nagao A, Kobayashi M, Koyasu S, Chow CCT, Harada H. HIF-1-dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance. Int J Mol Sci  2019; 20(2): 238.
[http://dx.doi.org/10.3390/ijms20020238] [PMID: 30634433] 
[288] 
Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab  2006; 3(3): 177-85.
[http://dx.doi.org/10.1016/j.cmet.2006.02.002] [PMID: 16517405] 
[289] 
Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab  2006; 3(3): 187-97.
[http://dx.doi.org/10.1016/j.cmet.2006.01.012] [PMID: 16517406] 
[290] 
Furuta E, Pai SK, Zhan R, et al. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res  2008; 68(4): 1003-11.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-2489] [PMID: 18281474] 
[291] 
Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, metabolism, and cancer. Cancer Discov  2015; 5(10): 1024-39.
[http://dx.doi.org/10.1158/2159-8290.CD-15-0507] [PMID: 26382145] 
[292] 
Prendergast GC, Ziff EB. A new bind for Myc. Trends Genet  1992; 8(3): 91-6.
[http://dx.doi.org/10.1016/0168-9525(92)90196-B] [PMID: 1579994] 
[293] 
Choi Y-K, Park K-G. Targeting glutamine metabolism for cancer treatment. Biomol Ther (Seoul)  2018; 26(1): 19-28.
[http://dx.doi.org/10.4062/biomolther.2017.178] [PMID: 29212303] 
[294] 
Wang T, Liu H, Lian G, Zhang S-Y, Wang X, Jiang C. HIF1α-induced glycolysis metabolism is essential to the activation of inflammatory macrophages. Mediators Inflamm  2017; 2017: 9029327-7.
[http://dx.doi.org/10.1155/2017/9029327] [PMID: 29386753] 
[295] 
Zimna A, Kurpisz M. Hypoxia-inducible factor-1 in physiological and pathophysiological angiogenesis: applications and therapies. BioMed Res Int  2015; 2015: 549412-2.
[http://dx.doi.org/10.1155/2015/549412] [PMID: 26146622] 
[296] 
Bensaad K, Favaro E, Lewis CA, et al. Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep  2014; 9(1): 349-65.
[http://dx.doi.org/10.1016/j.celrep.2014.08.056] [PMID: 25263561] 
[297] 
Dai M-S, Lu H. Crosstalk between c-Myc and ribosome in ribosomal biogenesis and cancer. J Cell Biochem  2008; 105(3): 670-7.
[http://dx.doi.org/10.1002/jcb.21895] [PMID: 18773413] 
[298] 
Schmidt EV. The role of c-myc in regulation of translation initiation. Oncogene  2004; 23(18): 3217-21.
[http://dx.doi.org/10.1038/sj.onc.1207548] [PMID: 15094771] 
[299] 
Carrella D, Manni I, Tumaini B, et al. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds. Oncotarget  2016; 7(37): 58743-58.
[http://dx.doi.org/10.18632/oncotarget.11318] [PMID: 27542212] 
[300] 
Hiraki M, Hwang S-Y, Cao S, et al. Small-molecule reactivation of mutant p53 to wild-type-like p53 through the p53-Hsp40 regulatory axis. Chem Biol  2015; 22(9): 1206-16.
[http://dx.doi.org/10.1016/j.chembiol.2015.07.016] [PMID: 26320861] 
[301] 
Soragni A, Janzen DM, Johnson LM, et al. A designed inhibitor of p53 aggregation rescues p53 tumor suppression in ovarian carcinomas. Cancer Cell  2016; 29(1): 90-103.
[http://dx.doi.org/10.1016/j.ccell.2015.12.002] [PMID: 26748848] 
[302] 
Cicenas J, Zalyte E, Rimkus A, Dapkus D, Noreika R, Urbonavicius S. JNK, p38, ERK, and SGK1 inhibitors in cancer. Cancers (Basel)  2017; 10(1): 1.
[http://dx.doi.org/10.3390/cancers10010001] [PMID: 29267206] 
[303] 
Grassi ES, Vezzoli V, Negri I, et al. SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways. Oncotarget  2015; 6(34): 36383-99.
[http://dx.doi.org/10.18632/oncotarget.5799] [PMID: 26415230] 
[304] 
Kim J-H, Kim TH, Kang HS, Ro J, Kim HS, Yoon S. SP600125, an inhibitor of Jnk pathway, reduces viability of relatively resistant cancer cells to doxorubicin. Biochem Biophys Res Commun  2009; 387(3): 450-5.
[http://dx.doi.org/10.1016/j.bbrc.2009.07.036] [PMID: 19607816] 
[305] 
Kim J-H, Chae M, Choi A-R, Sik Kim H, Yoon S. SP600125 overcomes antimitotic drug-resistance in cancer cells by increasing apoptosis with independence of P-gp inhibition. Eur J Pharmacol  2014; 723: 141-7.
[http://dx.doi.org/10.1016/j.ejphar.2013.11.026] [PMID: 24333214] 
[306] 
Lu Y-Y, Chen T-S, Wang X-P, Qu J-L, Chen M. The JNK inhibitor SP600125 enhances dihydroartemisinin-induced apoptosis by accelerating Bax translocation into mitochondria in human lung adenocarcinoma cells. FEBS Lett  2010; 584(18): 4019-26.
[http://dx.doi.org/10.1016/j.febslet.2010.08.014] [PMID: 20709060] 
[307] 
Lin Y, Zhang B, Liang H, et al. JNK inhibitor SP600125 enhances TGF-β-induced apoptosis of RBE human cholangiocarcinoma cells in a Smad-dependent manner. Mol Med Rep  2013; 8(6): 1623-9.
[http://dx.doi.org/10.3892/mmr.2013.1711] [PMID: 24100678] 
[308] 
Jemaà M, Vitale I, Kepp O, et al. Selective killing of p53-deficient cancer cells by SP600125. EMBO Mol Med  2012; 4(6): 500-14.
[http://dx.doi.org/10.1002/emmm.201200228] [PMID: 22438244] 
[309] 
Konno T, Ninomiya T, Kohno T, Kikuchi S, Sawada N, Kojima T. c-Jun N-terminal kinase inhibitor SP600125 enhances barrier function and elongation of human pancreatic cancer cell line HPAC in a Ca-switch model. Histochem Cell Biol  2015; 143(5): 471-9.
[http://dx.doi.org/10.1007/s00418-014-1300-4] [PMID: 25511417] 
[310] 
Li JY, Huang JY, Xing B, et al. SP600125, a JNK inhibitor, suppresses growth of JNK-inactive glioblastoma cells through cell-cycle G2/M phase arrest. Pharmazie  2012; 67(11): 942-6.
[PMID: 23210245] 
[311] 
Yasui H, Hideshima T, Ikeda H, et al. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. Br J Haematol  2007; 136(3): 414-23.
[http://dx.doi.org/10.1111/j.1365-2141.2006.06443.x] [PMID: 17173546] 
[312] 
He D, Zhao XQ, Chen XG, et al. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells. PLoS One  2013; 8(1): e54181-1.
[http://dx.doi.org/10.1371/journal.pone.0054181] [PMID: 23349819] 
[313] 
Porta C, Paglino C, Mosca A. targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol  2014; 4: 64-4.
[http://dx.doi.org/10.3389/fonc.2014.00064] [PMID: 24782981] 
[314] 
Belyea B, Kephart JG, Blum J, Kirsch DG, Linardic CM. Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. Sarcoma  2012; 2012: 406239-9.
[http://dx.doi.org/10.1155/2012/406239] [PMID: 22619564] 
[315] 
Lee SM, Moon J, Redman BG, et al. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer  2015; 121(3): 432-40.
[http://dx.doi.org/10.1002/cncr.29055] [PMID: 25250858] 
[316] 
Zhang M, Mathews Griner LA, Ju W, et al. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. Proc Natl Acad Sci USA  2015; 112(40): 12480-5.
[http://dx.doi.org/10.1073/pnas.1516208112] [PMID: 26396258] 
[317] 
Zimmerli D, Cecconi V, Valenta T, et al. WNT ligands control initiation and progression of human papillomavirus-driven squamous cell carcinoma. Oncogene  2018; 37(27): 3753-62.
[http://dx.doi.org/10.1038/s41388-018-0244-x] [PMID: 29662191] 
[318] 
Zhong Z, Sepramaniam S, Chew XH, et al. PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers. Oncogene  2019; 38(40): 6662-77.
[http://dx.doi.org/10.1038/s41388-019-0908-1] [PMID: 31391551] 
[319] 
Canesin G, Evans-Axelsson S, Hellsten R, et al. Treatment with the WNT5A-mimicking peptide foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One  2017; 12(9) e0184418
[http://dx.doi.org/10.1371/journal.pone.0184418] [PMID: 28886116] 
[320] 
Tornatore L, Sandomenico A, Raimondo D, et al. Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors. Cancer Cell  2014; 26(4): 495-508.
[http://dx.doi.org/10.1016/j.ccr.2014.07.027] [PMID: 25314077] 
[321] 
Yong H-Y, Koh M-S, Moon A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs  2009; 18(12): 1893-905.
[http://dx.doi.org/10.1517/13543780903321490] [PMID: 19852565] 
[322] 
Luistro L, He W, Smith M, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res  2009; 69(19): 7672-80.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-1843] [PMID: 19773430] 
[323] 
O’Shea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov  2004; 3(7): 555-64.
[http://dx.doi.org/10.1038/nrd1441] [PMID: 15232577] 
Cite As
Current Pharmaceutical Design

Exploring Dysregulated Signaling Pathways in Cancer

Abstract
